Objective Malignant grade and death rate are very high for non-small cell lung cancer (NSCLC), and gefitinib is a new molecule target anticancer drug. The aim of this meta analysis was to evaluate the clinical efficacy of gefitinib for NSCLC with mutation in epidermal growth factor receptor(EGFR). Methods We searched WP(2000—2011.06), wanfang (2000—2011.06), CNKI(2000—2011.06), OVID(2000—2011.06), Karger Online Jounals(2000—2011.06). Two reviewers independently evaluated the quality of the included studies and extracted the data. Meta-analyses were performed by RevMan 5.1 software. Results Ten studies involving 941 patients were included. The results of meta-analyses showed that: when gefitinib was used for NSCLC with mutation in EGFR compared to non-mutation, overall response rate increased(RR＝4.42, 95% CI: 3.49-5.60) and disease control rate also increased(RR＝1.79, 95% CI: 1.23～2.61) and the rate of disease progression decreased(RR＝0.24，95% CI: 0.18-0.32). Conclusion Gefitinib shows more superiority for NSCLC with EGFR mutation, and its clinical application is worthy to be advocated.